A phase 3 study of RM-493 (setmelanotide) to treat Bardet-Biedl Syndrome (BBS).
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Rhythm
- 10 Jan 2018 New trial record
- 04 Jan 2018 According to a Rhythm Pharmaceuticals media release, company expects to meet regulatory authorities in early 2018 to plan this trial.